News & Updates

The progression of COVID-19 disease during pregnancy from asymptomatic or mild symptoms to moderate, severe, or critical symptoms is consistent regardless of trimester, according to a prospective study presented at SMFM 2022.

Effective treatment with pre-exposure prophylaxis (PrEP) for HIV puts a cap on the additional cost patients should be willing to pay for long-acting injectable cabotegravir (CAB-LA), reports a US study.

Universal screening for hepatitis C virus (HCV) in pregnant individuals resulted in improved detection and a potential reduction in perinatal transmission, according to a study presented at CROI 2022.

First data from Vaccine Allergy Safety (VAS) clinics in Hong Kong show that a majority of high-risk patients can receive coronavirus disease 2019 (COVID-19) vaccination safely, with no immediate allergic reactions.

The combination of corticosteroid (CS) therapy with remdesivir (RDV) has noninferior survival outcomes relative to CS monotherapy in patients hospitalized with the coronavirus disease 2019 (COVID-19), reports a recent study.

The early addition of ivermectin to standard of care (SoC)* in high-risk patients with mild-to-moderate COVID-19 did not prevent progression to severe disease compared with SoC alone, according to results of the I-TECH** trial conducted in Malaysia.

There is an increased rate of hepatitis C virus (HCV) reinfection among people who inject drugs after the scale-up of direct-acting antivirals, reports a recent Scotland study.